Latest news and press releases about Regeneron Pharmaceuticals, Inc. (REGN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses.
Price
| Price | $726.47 |
| Market Cap | $74.8B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 17.55 |
| Price / Book | 2.40 |
| EV / EBITDA | 13.81 |
| Dividend Yield | 0.50% |
Profitability
| Return on Equity | 14.41% |
| Return on Invested Capital | 8.51% |
| Return on Assets | 11.11% |
| Gross Margin | 84.86% |
| Operating Margin | 25.56% |
| Net Margin | 27.86% |
Related companies: ALNY · ARGX · CI · COR · ELV · GMAB · IDXX
Explore sector: Healthcare · Biotechnology
More sections of REGN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks